CYP2D6 and CYP3A4 double transgenic mice

Human CYP2D6 and CYP3A4 collectively metabolize over 70% of drugs on the market. In an effort To study the developmental and sexual expression and regulation of these two major human drug-metabolizing P450s, a double transgenic mouse line carrying b oth CYP2D6 and CYP3A4 transgenes (Tg-CYP2D6/CYP3A4) was generated by a pharmaceutical scientist at the University at Buffalo in collaboration with researchers at the National Cancer Institute. The CYP2D6/CYP3A4 double trangenic mouse model could pro vide insight into potential differences in CYP expression and induction and effects on drug-drug interactions (DDIs) between men and women.

The mice and/or tissue samples are available for purchase and licensing.

Additional information can be f ound in DMD 36:435–441, 2008.

Categories: Research Tool

Type of Offer: Licensing



« More Medical Patents

---